Gastromedisinsk forskningsgruppe

Forskningsgruppe gastro
 

Fra venstre i bildet! Frode Lerang (Overlege dr.med), Magne Henriksen (Overlege, PhD), Henrik Wåhlberg (Lis-lege og stipendiat), Jan Novotny (Overlege), Nina Bråthen (studiesykepleier), Erik Christensen (Overlege), Taran Søberg (Overlege), Per Sandvei (Avdelingssjef, overlege), Lars-Petter Jelsness-Jørgensen (Forskningsgruppeleder, Professor PhD)

Gruppen jobber for å styrke forskning på ulike fordøyelsesrelaterte plager og sykdommer. Primærfokus er inflammatorisk tarmsykdom (IBD), gastrointestinale blødninger, pasientrapporterte utfallsmål


​Navn​
Arbeidssted​​Jobbtittel
​Tittel
Lars-Petter Jelsness-JørgensenSykehuset Østfold – Høgskolen i ØstfoldSeniorforsker - sykepleier

Leder av gruppen -

Professor

Frode LerangSykehuset ØstfoldOverlegeAkademisk stilling
Magne HenriksenSykehuset ØstfoldOverlegeAkademisk stilling
Per SandveiSykehuset ØstfoldAvdelingssjef
Akademisk stiling
Rogelio Barreto RiosSykehuset ØstfoldOverlege PhD
Taran SøbergSykehuset ØstfoldOverlege 
Kristina Aas Holten
Sykehuset ØstfoldLIS
 PhD stipendiat
Henrik Wåhlberg
Sykehuset Østfold
Overlege
 PhD
Kathrine Romstad
Sykehuset ØstfoldKst. overlege PhD stipendiat
Svein Oscar FrigstadSykehuset Asker og Bærum – Sykehuset ØstfoldSeksjonsoverlegePhD stipendiat



  • Kathrine Romstad: Blue-studien (UiO): Hovedfokus er blødende ulcussykdom
  • Svein Oskar Frigstad: Vitality studien: Vitamin D, prevalens og assosiasjoner til pasientrapporterte utfallsmål (UiO)



  • IBSEN III: Prospektiv, multisenter studie som kartlegger alle nydiagnostiserte tilfeller av inflammatorisk tarmsykdom. Studien har en bredt anlagt datainnsamling som inkluderer genetiske markører, kliniske data, endoskopi, ernæring, radiologi, mikrobiota, symptomer/livskvalitet og data relatert til sykefravær og uføretrygd.
  • Vitality: Multisenterstudie som kartlegger forekomst av vitamin d mangel blant pasienter med IBD, samt ulike pasientrapporterte endepunkter og helsetjenestekvalitet.
  • BioSTOP:  Multisenterstudie som kartlegger langtidseffekter knyttet til å stoppe eller kontinuere biologisk behandling hos pasienter med ulcerøs kolitt i vedvarende remisjon.
  • HpEUreg: Internasjonal studie og kartlegging av Helicobacter Pylori
  • Blue-studien: Kartlegging av blødende ulcusssykdom
  • Epos: Europeisk Polypp Observasjonsstudie. Kartlegging av oppfølginsprosedyrer/intervaller etter fjerning av polypper.


1. Jørgensen KK et. al. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching
from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
BioDrugs. 2020 Oct;34(5):681-694. doi: 10.1007/s40259-020-00438-7.

2. Klepp P et al. Risk of colorectal cancer in a population-based study 20 years after diagnosis of
ulcerative colitis: results from the IBSEN study. BMJ Open Gastroenterol. 2020 Mar 26;7(1):e000361.
doi: 10.1136/bmjgast-2019-000361. eCollection 2020.

3. Henriksen M, Høivik ML, Jelsness-Jørgensen LP, Moum B; IBSEN Study Group. Irritable Bowel-like
Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation:
Results From a Population-based Study [the IBSEN Study]. J Crohns Colitis. 2018 Mar 28;12(4):389-
393. doi: 10.1093/ecco-jcc/jjx152.

4. Ossum AM et al. Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term
Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study. J Crohns Colitis.
2018 Jan 5;12(1):96-104. doi: 10.1093/ecco-jcc/jjx126.

5. Lunder AK et. al. Bowel Damage in Patients With Long-term Crohn's Disease, Assessed by Magnetic
Resonance Enterography and the Lémann Index. Clin Gastroenterol Hepatol. 2018 Jan;16(1):75-82.e5.
doi: 10.1016/j.cgh.2017.06.053. Epub 2017 Jul 8.

6. Jørgensen KK et al; NOR-SWITCH study group. Switching from originator infliximab to biosimilar CTP13
compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week,
randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304-2316. doi:
10.1016/S0140-6736(17)30068-5. Epub 2017 May 11.

7. Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA. Malignancies in Patients with
Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. J Crohns Colitis.
2017 May 1;11(5):571-577. doi: 10.1093/ecco-jcc/jjw193.

8. Huppertz-Hauss G et al. Fatigue in a population-based cohort of patients with inflammatory bowel
disease 20 years after diagnosis: The IBSEN study. Scand J Gastroenterol. 2017 Mar;52(3):351-358.
doi: 10.1080/00365521.2016.1256425. Epub 2016 Nov 17.

9. Lunder AK et al. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance
Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology. 2016
Oct;151(4):660-669.e4. doi: 10.1053/j.gastro.2016.06.021. Epub 2016 Jun 21.

10. Nyssen OP et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and
trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
Gut. 2020 Sep 21:gutjnl-2020-321372. doi: 10.1136/gutjnl-2020-321372. Online ahead of print.

11. Romstad KK, Detlie TE, Søberg T, Ricanek P, Jahnsen ME, Lerang F, Jahnsen J. Gastrointestinal
bleeding due to peptic ulcers and erosions - a prospective observational study (BLUE study). Scand J
Gastroenterol. 2020 Oct;55(10):1139-1145. doi: 10.1080/00365521.2020.1819405. Epub 2020 Sep 15.

12. Hoff et al. Patient-reported adverse events after colonoscopy in Norway. Endoscopy. 2017
Aug;49(8):745-753. doi: 10.1055/s-0043-105265. Epub 2017 Apr 26.

13. Farrell D et al. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev.
2020 Apr 16;4(4):CD012005. doi: 10.1002/14651858.CD012005.pub2.

14. Opheim R et al. Self-esteem in patients with inflammatory bowel disease. Qual Life Res. 2020
Jul;29(7):1839-1846. doi: 10.1007/s11136-020-02467-9. Epub 2020 Mar 6.

15. Frigstad SO et al. Pain Severity and Vitamin D Deficiency in IBD Patients. Nutrients. 2019 Dec
20;12(1):26. doi: 10.3390/nu12010026.

16. Jelsness-Jørgensen LP, Bernklev T, Lundin KEA. Fatigue as an Extra-Intestinal Manifestation of Celiac
Disease: A Systematic Review. Nutrients. 2018 Nov 3;10(11):1652. doi: 10.3390/nu10111652.

17. Frigstad SO et al. Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease
patients. World J Gastroenterol. 2018 Aug 7;24(29):3293-3301. doi: 10.3748/wjg.v24.i29.3293.

18. Jelsness-Jørgensen LP et al. Pain may be an important factor to consider in inflammatory bowel
disease patients troubled by fatigue. United European Gastroenterol J. 2017 Aug;5(5):687-693. doi:
10.1177/2050640616674654. Epub

19. Dibley L et al. Identification of Research Priorities for Inflammatory Bowel Disease Nursing in Europe:
a Nurses-European Crohn's and Colitis Organisation Delphi Survey. J Crohns Colitis. 2017 Mar
1;11(3):353-359. doi: 10.1093/ecco-jcc/jjw164.




Sist oppdatert 22.11.2022